세계의 방광암 시장 평가 : 유형별, 양식별, 최종사용자별, 지역별, 기회 및 예측(2017-2031년)

Global bladder cancer market size was valued at USD 4.51 billion in 2023, which is expected to reach USD 6.81 billion in 2031, with a CAGR of 5.28% for the forecast period between 2024 and 2031. Numerous factors are propelling the global bladder cancer market, such as the increasing prevalence of bladder cancer, the growing geriatric population, technological advancements in diagnostic and treatment methodologies, government initiatives, and increasing funding for research and development. The rising prevalence of bladder cancer is a significant factor driving the global bladder cancer market.

Bladder cancer ranks as the 10th most common cancer worldwide. It can be attributed to various factors, including an aging population and increased exposure to environmental carcinogens. As the global population ages, the risk of bladder cancer increases, creating a growing demand for diagnostic and treatment options. Advancements in healthcare infrastructure and growing accessibility are contributing to the growth of global bladder cancer market. Better access to healthcare services, higher quality of care, and advanced facilities can lead to early detection and better outcomes for bladder cancer patients.

Innovations in imaging technologies, non-invasive urine tests, and molecular diagnostics have revolutionized early detection and monitoring, leading to better patient outcomes. Increasing consumption of tobacco and increased exposure to industrial chemicals play a significant role in bladder cancer development, surging the demand for the global bladder cancer market. The market is witnessing technological advancements such as minimally invasive surgical techniques, robotic-assisted surgery, and precision medicine which improves the effectiveness of treatments and enhance patient experiences. Government initiatives and research funding are contributing to market expansion. Growing investment in bladder cancer research, including clinical trials and drug development, is expediting innovation and introducing new therapies and diagnostic tools.

Rising Prevalence of Bladder Cancer

The increasing incidence and prevalence of bladder cancer play a significant role in the expansion of the global bladder cancer market. Bladder cancer, recognized as the 6th most widespread form of cancer worldwide, presents a distinct gender divide, with it being the 10th most common cancer among men and the 17th most prevalent among women. The high prevalence is shaped by a multitude of factors, including the aging population, heightened exposure to environmental carcinogens, and individual lifestyle choices. As the number of bladder cancer cases continues to rise, there is an increasing demand for advanced diagnostic techniques, treatment modalities, and healthcare provisions. The surge in demand stimulates research, fosters innovation, and attracts investments in the bladder cancer market, geared towards enhancing early detection, more advanced therapies, and increased patient care.

Technological Advancements

Recent technological advancements are pivotal in driving the global bladder cancer market forward. These medical technology innovations have revolutionized how bladder cancer is diagnosed, treated, and monitored. They encompass the creation of less invasive surgical techniques, the incorporation of precision-enhancing robotic-assisted surgery, and the introduction of personalized medicine approaches. These breakthroughs enhance treatments' efficacy and the overall patient experience by reducing invasiveness and speeding up recovery. Additionally, state-of-the-art imaging methods and diagnostic tools are facilitating early detection, which is a critical factor in enhancing bladder cancer outcomes. These technological advancements are at the forefront of shaping the growth and potential of the global bladder cancer market. UC San Diego Health became the first healthcare system to provide a new technology that uses white light, blue light, and an imaging dye that causes cancer cells to glow fluorescent pink to identify and monitor bladder cancer in both clinic and operating room settings in San Diego.

Government Initiatives

Governments around the globe are actively involved in various initiatives such as partnerships with various organizations to increase awareness about bladder cancer. These initiatives encompass the deployment of public health campaigns, the implementation of educational programs, and the provision of support for research endeavors. By prioritizing awareness, governments and collaborating organizations aim to educate the public about risk factors, symptoms, early detection, and the available resources for managing bladder cancer. It fosters a deeper understanding of the disease and motivates individuals to embrace preventive measures and seek prompt medical attention. Enhanced awareness can ultimately result in earlier diagnoses, improved treatment outcomes, and a decreased burden on healthcare systems, underscoring the significance of these global initiatives in the battle against bladder cancer.

Fight Bladder Cancer UK, a proactive national organization driven by patients, hosted a parliamentary event in May 2023. Fight Bladder Cancer places a strong emphasis on the significance of timely screening, urging people to remain vigilant regarding possible symptoms and promptly consult a healthcare professional. It involves raising awareness among healthcare practitioners about identifying early indicators and implementing effective diagnostic procedures.

Transitional Cell Carcinoma Dominated the Market

The global bladder cancer market is witnessing a surging need for treatments custom-tailored for transitional cell carcinoma (TCC). This type of bladder cancer comprises a substantial share of all bladder cancer cases. The growing demand can be ascribed to multiple factors, including the rising incidence of transitional cell carcinoma, advancements in diagnostic techniques enabling more precise TCC detection, and an increased emphasis on individualized treatment strategies. As awareness and comprehension of the distinctive attributes and treatment requisites of TCC broaden, pharmaceutical companies and healthcare providers are allocating resources to research and therapies that address the specific needs of this subset of bladder cancer patients.

In April 2023, the Japanese multinational pharmaceutical company Astellas Pharma disclosed that Food and Drug Administration (FDA) had issued accelerated approval for Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for the initial treatment of adults with locally advanced or metastatic transitional cell carcinoma who are not suitable candidates for cisplatin-containing chemotherapy.

Future Market Scenario

The outlook for the global bladder cancer market appears highly promising, owing to its exceptional opportunities. Bladder cancer ranks amongst the most prevalent cancers globally, rendering it a central focus for pharmaceutical and biotechnology firms. The increasing incidence of bladder cancer, influenced by factors such as an aging population, environmental factors, and evolving lifestyles, fuels a rising demand for innovative diagnostic tools and therapeutic interventions.

Furthermore, significant technological advancements have reshaped the landscape such as introduction of new treatments, precision medicine, and less invasive surgical methods that enhance patient outcomes. Strategic alliances and acquisitions among major industry players further amplify the market's growth potential, which stimulates collaborative research and development endeavors. With an expanding awareness and comprehension of bladder cancer, the market is primed to make substantial strides in the pursuit of more efficacious treatments, early detection, and enhanced patient care.

Key Players Landscape and Outlook

In the global bladder cancer market, prominent pharmaceutical and biotechnology firms are progressively entering into strategic alliances to seize the extensive prospects. These partnerships allow these companies to merge their knowledge, resources, and research endeavors, with the goal of creating innovative diagnostic tools, therapies, and treatment solutions. Moreover, these collaborative efforts facilitate the exchange of expertise and cutting-edge technologies, which are vital in addressing the intricacies of bladder cancer. By consolidating their capabilities, these companies aspire to expedite the development of pharmaceuticals, improve patient care, and meet the unfulfilled medical requirements in the domain. Ultimately, these partnerships empower the industry to cater to the escalating demand more effectively for bladder cancer treatments and diagnostic methods.

In October 2023, the European Union approved the acquisition of the biotechnology company Seagen, which specializes in innovative cancer treatments by Pfizer. The deal, valued at USD 43 billion, is set to broaden Pfizer's range of bladder cancer medications through the incorporation of Seagen's therapies.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Bladder Cancer Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. Value
  • 4.1.2. Volume
• 4.2. By Types
  • 4.2.1. Urothelial Carcinoma
  • 4.2.2. Adenocarcinoma
  • 4.2.3. Squamous Cell Carcinoma
  • 4.2.4. Others
• 4.3. By Modality
  • 4.3.1. Diagnosis
    • 4.3.1.1. Cytology
    • 4.3.1.2. Cystoscopy
    • 4.3.1.3. MRI Scan
    • 4.3.1.4. CT Scan
  • 4.3.2. Treatment
    • 4.3.2.1. Surgery
    • 4.3.2.2. Radiation Therapy
    • 4.3.2.3. Radiopharmaceuticals
    • 4.3.2.4. Transurethral Bladder Tumour Resection
    • 4.3.2.5. Chemotherapy
    • 4.3.2.6. Immunotherapy
    • 4.3.2.7. Gene Therapy
    • 4.3.2.8. Cryotherapy
    • 4.3.2.9. High-Intensity Focused Ultrasound
    • 4.3.2.10. Targeted Therapy
• 4.4. By End-user
  • 4.4.1. Hospitals
  • 4.4.2. Ambulatory Surgical Centers
  • 4.4.3. Specialty Clinics
  • 4.4.4. Pharmacies
  • 4.4.5. Others
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. South America
  • 4.5.4. Asia-Pacific
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global Bladder Cancer Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. Value
    • 5.1.1.2. Volume
  • 5.1.2. By Types
    • 5.1.2.1. Urothelial Carcinoma
    • 5.1.2.2. Adenocarcinoma
    • 5.1.2.3. Squamous Cell Carcinoma
    • 5.1.2.4. Others
  • 5.1.3. By Modality
    • 5.1.3.1. Diagnosis
    • 5.1.3.1.1. Cytology
    • 5.1.3.1.2. Cystoscopy
    • 5.1.3.1.3. MRI Scan
    • 5.1.3.1.4. CT Scan
    • 5.1.3.2. Treatment
    • 5.1.3.2.1. Surgery
    • 5.1.3.2.2. Radiation Therapy
    • 5.1.3.2.3. Radiopharmaceuticals
    • 5.1.3.2.4. Transurethral Bladder Tumour Resection
    • 5.1.3.2.5. Chemotherapy
    • 5.1.3.2.6. Immunotherapy
    • 5.1.3.2.7. Gene Therapy
    • 5.1.3.2.8. Cryotherapy
    • 5.1.3.2.9. High-Intensity Focused Ultrasound
    • 5.1.3.2.10. Targeted Therapy
  • 5.1.4. By End-user
    • 5.1.4.1. Hospitals
    • 5.1.4.2. Ambulatory Surgical Centers
    • 5.1.4.3. Specialty Clinics
    • 5.1.4.4. Pharmacies
    • 5.1.4.5. Others
  • 5.1.5. United States*
    • 5.1.5.1. Market Size and Forecast
    • 5.1.5.1.1. Value
    • 5.1.5.1.2. Volume
    • 5.1.5.2. By Types
    • 5.1.5.2.1. Urothelial Carcinoma
    • 5.1.5.2.2. Adenocarcinoma
    • 5.1.5.2.3. Squamous Cell Carcinoma
    • 5.1.5.2.4. Others
    • 5.1.5.3. By Modality
    • 5.1.5.3.1. Diagnosis
    • 5.1.5.3.1.1. Cytology
    • 5.1.5.3.1.2. Cystoscopy
    • 5.1.5.3.1.3. MRI Scan
    • 5.1.5.3.1.4. CT Scan
    • 5.1.5.3.2. Treatment
    • 5.1.5.3.2.1. Surgery
    • 5.1.5.3.2.2. Radiation Therapy
    • 5.1.5.3.2.3. Radiopharmaceuticals
    • 5.1.5.3.2.4. Transurethral Bladder Tumour Resection
    • 5.1.5.3.2.5. Chemotherapy
    • 5.1.5.3.2.6. Immunotherapy
    • 5.1.5.3.2.7. Gene Therapy
    • 5.1.5.3.2.8. Cryotherapy
    • 5.1.5.3.2.9. High-Intensity Focused Ultrasound
    • 5.1.5.3.2.10. Targeted Therapy
    • 5.1.5.4. By End-user
    • 5.1.5.4.1. Hospitals
    • 5.1.5.4.2. Ambulatory Surgical Centers
    • 5.1.5.4.3. Specialty Clinics
    • 5.1.5.4.4. Pharmacies
    • 5.1.5.4.5. Others
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. South America
  • 5.3.1. Brazil
  • 5.3.2. Argentina
• 5.4. Asia-Pacific
  • 5.4.1. India
  • 5.4.2. China
  • 5.4.3. Japan
  • 5.4.4. Australia
  • 5.4.5. Vietnam
  • 5.4.6. South Korea
  • 5.4.7. Indonesia
  • 5.4.8. Philippines
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Types
• 6.2. By Modality
• 6.3. By End-user
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Supply Demand Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)
• 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Astellas Pharma Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. AstraZeneca plc
• 13.3. Johnson & Johnson Innovative Medicine
• 13.4. Bayer AG
• 13.5. Merck & Co., Inc.
• 13.6. Pfizer, Inc.
• 13.7. Ferring B.V.
• 13.8. Seagen Inc.
• 13.9. Asieris Pharmaceuticals
• 13.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer